Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy.
paper
Cited
Public
Unavailable
- Authors
- Desai, Brinda S; Monahan, Angela J; Carvey, Paul M; Hendey, Bill
- Year
- 2007
- Journal
- Cell transplantation
- PMID
- 17503739
- DOI
- 10.3727/000000007783464731
The blood-brain barrier (BBB) is a tightly regulated barrier in the central nervous system. Though the BBB is thought to be intact during neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), recent evidence argues otherwise. Dysfunction of the BBB may be involved in disease progression, eliciting of peripheral immune response, and, most importantly, altered drug efficacy. In this review, we will give a brief overview of the BBB, its components, and their functions. We will critically evaluate the current literature in AD and PD BBB pathology resulting from insult, neuroinflammation, and neurodegeneration. Specifically, we will discuss alterations in tight junction, transport and endothelial cell surface proteins, and vascular density changes, all of which result in altered permeability. Finally, we will discuss the implications of BBB dysfunction in current and future therapeutics. Developing a better appreciation of BBB dysfunction in AD and PD may not only provide novel strategies in treatment, but will prove an interesting milestone in understanding neurodegenerative disease etiology and progression.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| D-mannose alleviates rotenone-induced PD mouse model through microbiota-gut-brain axis. | Hong Y et al. | β | 2026 | β |
| Intermittent fasting protects MPTP-induced Parkinson's disease mouse model through regulating gut microbiota dysbiosis. | Qu Y et al. | β | 2026 | β |
| Nose to Brain Delivery of Curcumin Loaded Therapeutic Nanostructures for Neurodegenerative Diseases. | Kalita R et al. | β | 2026 | β |
| Taurine modulates gut microbiota and attenuates inο¬ammation in a rotenone-induced mouse model of Parkinson's disease. | Zhu Y et al. | β | 2026 | β |
| Beta-caryophyllene inhibits the permeability of the blood-brain barrier in MPTP-induced parkinsonism. | Ramos-Molina AR et al. | β | 2025 | β |
| Claudin-5 and occludin levels in patients with psychiatric disorders - A systematic review. | Maridaki Z et al. | β | 2025 | β |
| Claudin proteins and hemorrhage severity in aneurysmal subarachnoid hemorrhage: Correlation with modified Fisher score but not functional outcome. | Lenzser G et al. | β | 2025 | β |
| Designing a Small Molecule for PET Radiotracing: [<sup>18</sup>F]MC225 in Human Trials for Early Diagnosis in CNS Pathologies. | Mastropasqua F et al. | β | 2025 | β |
| Examining Stromal Cell Interactions in an In Vitro Blood-Brain Barrier Model with Human Umbilical Vein Endothelial Cells. | Margari A et al. | β | 2025 | β |
| HIV-associated neurocognitive disorders (HAND): Optimal diagnosis, antiviral therapy, pharmacological treatment, management, and future scopes. | Adhikary K et al. | β | 2025 | β |
| Increasing interleukin-17 induced by Ξ²-Amyloid deposition is involved in early cognitive decline after sevoflurane anesthesia. | Zhao Q et al. | β | 2025 | β |
| Mechanobiology of the blood-brain barrier during development, disease and ageing. | Konig S et al. | β | 2025 | β |
| Microfluidic and Computational Tools for Neurodegeneration Studies. | Gomez K et al. | β | 2025 | β |
| The critical role of GLP-1 signaling pathways in the pathology of Parkinson's disease and diabetes. | Chen J et al. | β | 2025 | β |
| The role of reactive oxygen species in the regulation of the blood-brain barrier. | Shuvalova M et al. | β | 2025 | β |
| Unveiling the Mysteries of the Blood-brain Barrier: The Problem of the Brain/spinal Pharmacotherapy. | Walia A et al. | β | 2025 | β |
| Volumetric Analysis of the Blood-Brain Barrier After Ischemic Stroke by Electron Tomography in Mice. | Kotchetkov P et al. | β | 2025 | β |
| Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs-Protocols and Advice for the FDA to Meet the ALS Act Vision. | Niazi SK | β | 2024 | β |
| Blood-brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy. | Lau K et al. | β | 2024 | β |
| Brain Targeting Nanomedicines: Pitfalls and Promise. | Kakinen A et al. | β | 2024 | β |
| Cerebrospinal fluid proteomics reveals the innate immunity and blood-brain barrier dysregulation in a patient with multidrug-resistant <i>Acinetobacter baumannii</i> ventriculitis treated with intrathecal and intravenous polymyxin B. | Li M et al. | β | 2024 | β |
| Detrimental Roles of Hypoxia-Inducible Factor-1Ξ± in Severe Hypoxic Brain Diseases. | Choi YK | β | 2024 | β |
| Lutein and the Underlying Neuroprotective Promise against Neurodegenerative Diseases. | Iyer S et al. | β | 2024 | β |
| Microphysiological Blood-Brain Barrier Systems for Disease Modeling and Drug Development. | Mulay AR et al. | β | 2024 | β |
| Modular tissue-in-a-CUBE platform to model blood-brain barrier (BBB) and brain interaction. | Koh I et al. | β | 2024 | β |
| Parkinson Disease -Targeted Nanocapsules for Synergistic Treatment: Combining Dopamine Replacement and Neuroinflammation Mitigation. | Liu Z et al. | β | 2024 | β |
| Pericyte derivation and transplantation for blood-CNS barrier reconstitution in CNS disorders. | Kim HW et al. | β | 2024 | β |
| Plasma lipidomics in early APP/PS1 female mouse model and its relationship with brain: Is it affected by the estrous cycle? | FerrΓ©-GonzΓ‘lez L et al. | β | 2024 | β |
| Progress in the Treatment of Central Nervous System Diseases Based on Nanosized Traditional Chinese Medicine. | Li J et al. | β | 2024 | β |
| Role of Oxidative Stress in Blood-Brain Barrier Disruption and Neurodegenerative Diseases. | Kim S et al. | β | 2024 | β |
| Role of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier. | Cazalla E et al. | β | 2024 | β |
| Small Particles, Big Potential: Polymeric Nanoparticles for Drug Delivery in Parkinson's Disease. | Virameteekul S et al. | β | 2024 | β |
| Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments. | Guglielmi G et al. | β | 2024 | β |
| The Common Denominators of Parkinson's Disease Pathogenesis and Methamphetamine Abuse. | Vincent B et al. | β | 2024 | β |
| The potential protective role of peripheral immunophenotypes in Alzheimer's disease: a Mendelian randomization study. | Zuo CY et al. | β | 2024 | β |
| Thyroid Hormone and Alzheimer Disease: Bridging Epidemiology to Mechanism. | Escamilla S et al. | β | 2024 | β |
| Aquaporin 4 beyond a water channel; participation in motor, sensory, cognitive and psychological performances, a comprehensive review. | Jazaeri SZ et al. | β | 2023 | β |
| BBB-on-a-chip with integrated micro-TEER for permeability evaluation of multi-functionalized gold nanorods against Alzheimer's disease. | Palma-Florez S et al. | β | 2023 | β |
| Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson's disease mouse model. | Mobahat M et al. | β | 2023 | β |
| Data-Driven Approaches Used for Compound Library Design for the Treatment of Parkinson's Disease. | Barrera-Vazquez O et al. | β | 2023 | β |
| Differential responses of primary neuron-secreted MCP-1 and IL-9 to type 2 diabetes and Alzheimerβs disease-associated metabolites | Ball BK et al. | β | 2023 | β |
| Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease. | Contaldi E et al. | β | 2023 | β |
| Endothelial Dysfunction in Neurodegenerative Diseases. | Fang YC et al. | β | 2023 | β |
| Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson's Disease. | Huang R et al. | β | 2023 | β |
| GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson's Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson's Disease-Relevant Pathogenic Mechanisms. | Schneider JS | β | 2023 | β |
| Heterochromatic silencing of immune-related genes in glia is required for BBB integrity and normal lifespan in drosophila. | Shu S et al. | β | 2023 | β |
| Identification of mitochondrial-related genes as potential biomarkers for the subtyping and prediction of Alzheimer's disease. | Ma W et al. | β | 2023 | β |
| Interplay between Systemic Glycemia and Neuroprotective Activity of Resveratrol in Modulating Astrocyte SIRT1 Response to Neuroinflammation. | Grabowska AD et al. | β | 2023 | β |
| Non-contrast estimate of blood-brain barrier permeability in humans using arterial spin labeling and magnetization transfer at 7Β T. | Mahmud SZ et al. | β | 2023 | β |
| Novel Therapeutic Opportunities for Neurodegenerative Diseases with Mesenchymal Stem Cells: The Focus on Modulating the Blood-Brain Barrier. | Vargas-RodrΓguez P et al. | β | 2023 | β |
| Pathophysiological Role of Microglial Activation Induced by Blood-Borne Proteins in Alzheimer's Disease. | Kim S et al. | β | 2023 | β |
| Protein aggregation-inhibition: a therapeutic route from Parkinson's disease to sickle cell anemia. | Martins GF et al. | β | 2023 | β |
| Proteins and Transcriptional Dysregulation of the Brain Extracellular Matrix in Parkinson's Disease: A Systematic Review. | Rike WA et al. | β | 2023 | β |
| The effects of Korean Red Ginseng on heme oxygenase-1 with a focus on mitochondrial function in pathophysiologic conditions. | Kim CH et al. | β | 2023 | β |
| The Impact of Persistent Noise Exposure under Inflammatory Conditions. | Cho I et al. | β | 2023 | β |
| The mechanisms of perineuronal net abnormalities in contributing aging and neurological diseases. | Dong Y et al. | β | 2023 | β |
| Therapeutic properties and pharmacological activities of asiaticoside and madecassoside: A review. | Bandopadhyay S et al. | β | 2023 | β |
| A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease. | Schneider JS | β | 2022 | β |
| Addressing Blood-Brain Barrier Impairment in Alzheimer's Disease. | Sharma C et al. | β | 2022 | β |
| Adolescent intermittent ethanol exposure produces Sex-Specific changes in BBB Permeability: A potential role for VEGFA. | Vore AS et al. | β | 2022 | β |
| Age-related brain atrophy is not a homogenous process: Different functional brain networks associate differentially with aging and blood factors. | Markov NT et al. | β | 2022 | β |
| Alcohol, inflammation, and blood-brain barrier function in health and disease across development. | Vore AS et al. | β | 2022 | β |
| Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson's disease. | Choudhury SP et al. | β | 2022 | β |
| A potent and selective inhibitor for the modulation of MAGL activity in the neurovasculature. | Kemble AM et al. | β | 2022 | β |
| A Single Domain Shark Antibody Targeting the Transferrin Receptor 1 Delivers a TrkB Agonist Antibody to the Brain and Provides Full Neuroprotection in a Mouse Model of Parkinson's Disease. | Clarke E et al. | β | 2022 | β |
| Critical Role of Neuronal Vps35 in Blood Vessel Branching and Maturation in Developing Mouse Brain. | Zhao Y et al. | β | 2022 | β |
| Do Periodontal Pathogens or Associated Virulence Factors Have a Deleterious Effect on the Blood-Brain Barrier, Contributing to Alzheimer's Disease? | Kouki MA et al. | β | 2022 | β |
| Emerging contributions of formyl peptide receptors to neurodegenerative diseases. | Busch L et al. | β | 2022 | β |
| Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives. | La Barbera L et al. | β | 2022 | β |
| Insights into the role of neutrophils in neuropsychiatric systemic lupus erythematosus: Current understanding and future directions. | Sim TM et al. | β | 2022 | β |
| Modeling the blood-brain barrier for treatment of central nervous system (CNS) diseases. | Rice O et al. | β | 2022 | β |
| Peptide-decorated nanocarriers penetrating the blood-brain barrier for imaging and therapy of brain diseases. | Gao X et al. | β | 2022 | β |
| Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson's disease. | Cuevas E et al. | β | 2022 | β |
| Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models. | Carpanini SM et al. | β | 2022 | β |
| The emerging role of the microbiome in Alzheimer's disease. | WasΓ©n C et al. | β | 2022 | β |
| Transcriptome sequencing reveals circRNA expression profile in Parkinson's disease-like mice after aerobic exercise. | Fan T et al. | β | 2022 | β |
| VEGF signalling causes stalls in brain capillaries and reduces cerebral blood flow in Alzheimer's mice. | Ali M et al. | β | 2022 | β |
| A deep learning approach to predict blood-brain barrier permeability. | Alsenan S et al. | β | 2021 | β |
| A Hybrid Nanofiber/Paper Cell Culture Platform for Building a 3D Blood-brain Barrier Model. | Huang K et al. | β | 2021 | β |
| An Investigation for Large Volume, Focal Blood-Brain Barrier Disruption with High-Frequency Pulsed Electric Fields. | Lorenzo MF et al. | β | 2021 | β |
| Associations among Cognitive Functions, Plasma DNA, and Diffusion Tensor Image along the Perivascular Space (DTI-ALPS) in Patients with Parkinson's Disease. | Chen HL et al. | β | 2021 | β |
| A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models. | Kumar V et al. | β | 2021 | β |
| Blood-Brain Barrier Disruption by Lipopolysaccharide and Sepsis-Associated Encephalopathy. | Peng X et al. | β | 2021 | β |
| Clonal haematopoiesis of emerging significance. | Hammond D et al. | β | 2021 | β |
| Degenerative disease-on-a-chip: Developing microfluidic models for rapid availability of newer therapies. | Jahagirdar D et al. | β | 2021 | β |
| Emerging Brain-Pathophysiology-Mimetic Platforms for Studying Neurodegenerative Diseases: Brain Organoids and Brains-on-a-Chip. | Bang S et al. | β | 2021 | β |
| Inhibition of vascular adhesion protein 1 protects dopamine neurons from the effects of acute inflammation and restores habit learning in the striatum. | Becchi S et al. | β | 2021 | β |
| Involvement of Testosterone Signaling in the Integrity of the Neurovascular Unit in the Male: Review of Evidence, Contradictions, and Hypothesis. | Ahmadpour D et al. | β | 2021 | β |
| Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson's Disease. | Wu Z et al. | β | 2021 | β |
| Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption. | Pediaditakis I et al. | β | 2021 | β |
| Modification of Glial Cell Activation through Dendritic Cell Vaccination: Promises for Treatment of Neurodegenerative Diseases. | Sabahi M et al. | β | 2021 | β |
| Network Analysis of the CSF Proteome Characterizes Convergent Pathways of Cellular Dysfunction in ALS. | Thompson AG et al. | β | 2021 | β |
| Novel compound FLZ alleviates rotenone-induced PD mouse model by suppressing TLR4/MyD88/NF-<i>ΞΊ</i>B pathway through microbiota-gut-brain axis. | Zhao Z et al. | β | 2021 | β |
| Role of ginseng in the neurovascular unit of neuroinflammatory diseases focused on the blood-brain barrier. | Kim M et al. | β | 2021 | β |
| Roles of Non-Coding RNAs as Novel Diagnostic Biomarkers in Parkinson's Disease. | Manna I et al. | β | 2021 | β |
| Sex differences in the blood-brain barrier and neurodegenerative diseases. | Weber CM et al. | β | 2021 | β |
| The Mechanisms of Sevoflurane-Induced Neuroinflammation. | Huang X et al. | β | 2021 | β |
| Three-Dimensional <i>in vitro</i> Models of Healthy and Tumor Brain Microvasculature for Drug and Toxicity Screening. | Piantino M et al. | β | 2021 | β |
| Treatment and protective effects of metalloproteinase inhibitors alone and in combination with N-Acetyl cysteine plus vitamin E in rats exposed to aflatoxin B<sub>1</sub>. | Tras B et al. | β | 2021 | β |
| Using multi-organ culture systems to study Parkinson's disease. | Reiner O et al. | β | 2021 | β |
| A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. | Kadry H et al. | β | 2020 | β |
| A glycomics and proteomics study of aging and Parkinson's disease in human brain. | Raghunathan R et al. | β | 2020 | β |
| Blood-Brain Barrier: More Contributor to Disruption of Central Nervous System Homeostasis Than Victim in Neurological Disorders. | Xiao M et al. | β | 2020 | β |
| Brain Disorders and Chemical Pollutants: A Gap Junction Link? | Mesnil M et al. | β | 2020 | β |
| Cerebrospinal fluid proteomics implicates the granin family in Parkinson's disease. | Rotunno MS et al. | β | 2020 | β |
| Erythrocytic Ξ±-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis. | Sheng L et al. | β | 2020 | β |
| GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration. | Chiricozzi E et al. | β | 2020 | β |
| Human iPSC-Derived Blood-Brain Barrier Models: Valuable Tools for Preclinical Drug Discovery and Development? | Appelt-Menzel A et al. | β | 2020 | β |
| [Immunological aspects of Parkinson's disease]. | Belova OV et al. | β | 2020 | β |
| Improvement of Impaired Motor Functions by Human Dental Exfoliated Deciduous Teeth Stem Cell-Derived Factors in a Rat Model of Parkinson's Disease. | Chen YR et al. | β | 2020 | β |
| Non-Coding RNAs in the Brain-Heart Axis: The Case of Parkinson's Disease. | Acharya S et al. | β | 2020 | β |
| Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. | Cutillo G et al. | β | 2020 | β |
| Plasma ubiquitin C-terminal hydrolase L1 levels reflect disease stage and motor severity in Parkinson's disease. | Ng ASL et al. | β | 2020 | β |
| Pulse Pressure: An Emerging Therapeutic Target for Dementia. | Levin RA et al. | β | 2020 | β |
| Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules. | Harilal S et al. | β | 2020 | β |
| Stem Cell Therapy for Neurodegenerative Diseases: How Do Stem Cells Bypass the Blood-Brain Barrier and Home to the Brain? | Chia YC et al. | β | 2020 | β |
| Tau Protein and Its Role in Blood-Brain Barrier Dysfunction. | Michalicova A et al. | β | 2020 | β |
| The Protective Effect of Exercise in Neurodegenerative Diseases: The Potential Role of Extracellular Vesicles. | Fuller OK et al. | β | 2020 | β |
| The Role of Neurovascular System in Neurodegenerative Diseases. | Ahmad A et al. | β | 2020 | β |
| Ultrasonic stimulation of the brain to enhance the release of dopamine - A potential novel treatment for Parkinson's disease. | Xu T et al. | β | 2020 | β |
| Understanding Human Cerebral Malaria through a Blood Transcriptomic Signature: Evidences for Erythrocyte Alteration, Immune/Inflammatory Dysregulation, and Brain Dysfunction. | Cabantous S et al. | β | 2020 | β |
| Exercise and Neuroinflammation in Health and Disease. | Seo DY et al. | β | 2019 | β |
| Human Bone Marrow Endothelial Progenitor Cell Transplantation into Symptomatic ALS Mice Delays Disease Progression and Increases Motor Neuron Survival by Repairing Blood-Spinal Cord Barrier. | Garbuzova-Davis S et al. | β | 2019 | β |
| Modeling Alzheimer's disease with human iPS cells: advancements, lessons, and applications. | Essayan-Perez S et al. | β | 2019 | β |
| Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease. | Ozkizilcik A et al. | β | 2019 | β |
| Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson's disease mouse model: Endothelial and microglial effects. | Burks S et al. | β | 2019 | β |
| Plasma Rich in Growth Factors (PRGF) Disrupt the Blood-Brain Barrier Integrity and Elevate Amyloid Pathology in the Brains of 5XFAD Mice. | Duong QV et al. | β | 2019 | β |
| Targeting the transferrin receptor for brain drug delivery. | Johnsen KB et al. | β | 2019 | β |
| The role of mutations associated with familial neurodegenerative disorders on blood-brain barrier function in an iPSC model. | Katt ME et al. | β | 2019 | β |
| Acteoside protects against 6-OHDA-induced dopaminergic neuron damage via Nrf2-ARE signaling pathway. | Li M et al. | β | 2018 | β |
| Activated Microglia Disrupt the Blood-Brain Barrier and Induce Chemokines and Cytokines in a Rat <i>in vitro</i> Model. | Shigemoto-Mogami Y et al. | β | 2018 | β |
| Cerebrospinal Fluid C-Reactive Protein in Parkinson's Disease: Associations with Motor and Non-motor Symptoms. | Sanjari Moghaddam H et al. | β | 2018 | β |
| Condition-specific gene co-expression network mining identifies key pathways and regulators in the brain tissue of Alzheimer's disease patients. | Xiang S et al. | β | 2018 | β |
| Decoding Common Features of Neurodegenerative Disorders: From Differentially Expressed Genes to Pathways. | Habib R et al. | β | 2018 | β |
| Efflux proteins at the blood-brain barrier: review and bioinformatics analysis. | Saidijam M et al. | β | 2018 | β |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | β | 2018 | β |
| High prevalence of focal and multi-focal somatic genetic variants in the human brain. | Keogh MJ et al. | β | 2018 | β |
| In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease. | Hu XM et al. | β | 2018 | β |
| New Targets for Parkinson's Disease: Adhesion G Protein-Coupled Receptor B1 is Downregulated by AMP-Activated Protein Kinase Activation. | Choi JS et al. | β | 2018 | β |
| Non-contrast MR imaging of blood-brain barrier permeability to water. | Lin Z et al. | β | 2018 | β |
| Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. | Furtado D et al. | β | 2018 | β |
| Role of Blood-Brain Barrier in Alzheimer's Disease. | Cai Z et al. | β | 2018 | β |
| Role of proteoglycans in neuro-inflammation and central nervous system fibrosis. | Heindryckx F et al. | β | 2018 | β |
| Temporal and Spatial Effects of Blast Overpressure on Blood-Brain Barrier Permeability in Traumatic Brain Injury. | Kuriakose M et al. | β | 2018 | β |
| Updates on immunity and inflammation in Parkinson disease pathology. | Joshi N et al. | β | 2018 | β |
| Claudin-5 regulates blood-brain barrier permeability by modifying brain microvascular endothelial cell proliferation, migration, and adhesion to prevent lung cancer metastasis. | Ma SC et al. | β | 2017 | β |
| Current and emerging brain applications of MR-guided focused ultrasound. | Meng Y et al. | β | 2017 | β |
| Identification of potential therapeutic compounds for Parkinson's disease using Drosophila and human cell models. | Sanz FJ et al. | β | 2017 | β |
| Improved Method for the Establishment of an In Vitro Blood-Brain Barrier Model Based on Porcine Brain Endothelial Cells. | Nielsen SSE et al. | β | 2017 | β |
| InΒ Vitro Modeling of Blood-Brain Barrier with Human iPSC-Derived Endothelial Cells, Pericytes, Neurons, and Astrocytes via Notch Signaling. | Yamamizu K et al. | β | 2017 | β |
| KDM4B histone demethylase and G9a regulate expression of vascular adhesion proteins in cerebral microvessels. | Choi JY et al. | β | 2017 | β |
| Paving the Way Toward Complex Blood-Brain Barrier Models Using Pluripotent Stem Cells. | Lauschke K et al. | β | 2017 | β |
| Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis. | Liu YD et al. | β | 2017 | β |
| Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease. | Zhang QS et al. | β | 2017 | β |
| T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer's Disease: Potential Pools of New Biomarkers. | Mietelska-Porowska A et al. | β | 2017 | β |
| CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease. | Chung YC et al. | β | 2016 | β |
| Chronic cerebral hypoperfusion induces memory deficits and facilitates AΞ² generation in C57BL/6J mice. | Wang L et al. | β | 2016 | β |
| CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. | Shi M et al. | β | 2016 | β |
| Microglia in Alzheimer's disease: A multifaceted relationship. | ElAli A et al. | β | 2016 | β |
| Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases. | Walker DG et al. | β | 2015 | β |
| An Effective Method to Identify Shared Pathways and Common Factors among Neurodegenerative Diseases. | Li P et al. | β | 2015 | β |
| Inhibition of Calpain Activation Protects MPTP-Induced Nigral and Spinal Cord Neurodegeneration, Reduces Inflammation, and Improves Gait Dynamics in Mice. | Samantaray S et al. | β | 2015 | β |
| Mesenchymal stem cells stabilize the blood-brain barrier through regulation of astrocytes. | Park HJ et al. | β | 2015 | β |
| Myeloid Dendritic Cells are Potential Players in Human Neurodegenerative Diseases. | BossΓΉ P et al. | β | 2015 | β |
| Reduction of glutamate-induced excitotoxicity in murine primary neurons involving calpain inhibition. | Gold M et al. | β | 2015 | β |
| Role of Immunity and Inflammation in the Pathophysiology of Neurodegenerative Diseases. | Fakhoury M | β | 2015 | β |
| Systems biology of neurodegenerative diseases. | Wood LB et al. | β | 2015 | β |
| Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. | Blair LJ et al. | β | 2015 | β |
| The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease. | Inekci D et al. | β | 2015 | β |
| Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome? | Banik A et al. | β | 2015 | β |
| Alzheimer disease and cellular mechanisms of memory storage. | Arshavsky YI | β | 2014 | β |
| Intravenous ascorbate improves spatial memory in middle-aged APP/PSEN1 and wild type mice. | Kennard JA et al. | β | 2014 | β |
| Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre. | Cai SC et al. | β | 2014 | β |
| Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model. | Sarkar S et al. | β | 2014 | β |
| Pathogenic role of ganglioside metabolism in neurodegenerative diseases. | Ariga T | β | 2014 | β |
| Plasma exosomal Ξ±-synuclein is likely CNS-derived and increased in Parkinson's disease. | Shi M et al. | β | 2014 | β |
| Public health and components of particulate matter: the changing assessment of black carbon. | Grahame TJ et al. | β | 2014 | β |
| Redox control of microglial function: molecular mechanisms and functional significance. | Rojo AI et al. | β | 2014 | β |
| Targeted discovery and validation of plasma biomarkers of Parkinson's disease. | Pan C et al. | β | 2014 | β |
| T-Lymphocyte Deficiency Exacerbates Behavioral Deficits in the 6-OHDA Unilateral Lesion Rat Model for Parkinson's Disease. | Wheeler CJ et al. | β | 2014 | β |
| Anti-Chol-1 antigen, GQ1bΞ±, antibodies are associated with Alzheimer's disease. | Ariga T et al. | β | 2013 | β |
| Biological activities of the LXRΞ± and Ξ² agonist, 4Ξ²-hydroxycholesterol, and of its isomer, 4Ξ±-hydroxycholesterol, on oligodendrocytes: effects on cell growth and viability, oxidative and inflammatory status. | Nury T et al. | β | 2013 | β |
| Changes in the blood-brain barrier status closely correlate with the rate of disease progression in patients with multiple system atrophy: a longitudinal study. | Lee JE et al. | β | 2013 | β |
| Characterization of peripheral hematopoietic stem cells and monocytes in Parkinson's disease. | Funk N et al. | β | 2013 | β |
| Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. | Theunis C et al. | β | 2013 | β |
| IFN-Ξ³ Production by amyloid Ξ²-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. | Browne TC et al. | β | 2013 | β |
| Immunologic privilege in the central nervous system and the blood-brain barrier. | Muldoon LL et al. | β | 2013 | β |
| Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation. | ElAli A et al. | β | 2013 | β |
| MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease. | Chung YC et al. | β | 2013 | β |
| Nerves and neovessels inhibit each other in the cornea. | Ferrari G et al. | β | 2013 | β |
| Neuroimmunological processes in Parkinson's disease and their relation to Ξ±-synuclein: microglia as the referee between neuronal processes and peripheral immunity. | Sanchez-Guajardo V et al. | β | 2013 | β |
| Neurovascular abnormalities in humans and mice with Huntington's disease. | Lin CY et al. | β | 2013 | β |
| Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. | Ramanan VK et al. | β | 2013 | β |
| The blood-brain barrier: an engineering perspective. | Wong AD et al. | β | 2013 | β |
| The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease. | Elali A et al. | β | 2013 | β |
| Immunology meets neuroscience--opportunities for immune intervention in neurodegenerative diseases. | Lynch MA et al. | β | 2012 | β |
| Inflammation and adaptive immunity in Parkinson's disease. | Mosley RL et al. | β | 2012 | β |
| Modern methods for delivery of drugs across the blood-brain barrier. | Chen Y et al. | β | 2012 | β |
| Neurovascular unit: a focus on pericytes. | SΓ‘-Pereira I et al. | β | 2012 | β |
| Survival of transplanted human neural stem cell line (ReNcell VM) into the rat brain with and without immunosuppression. | Hovakimyan M et al. | β | 2012 | β |
| Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances. | Liu WY et al. | β | 2012 | β |
| Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy. | Winston A et al. | β | 2012 | β |
| Blood-brain barrier impairment is functionally correlated with clinical severity in patients of multiple system atrophy. | Song SK et al. | β | 2011 | β |
| Identifying consensus disease pathways in Parkinson's disease using an integrative systems biology approach. | Edwards YJ et al. | β | 2011 | β |
| Pathways towards an effective immunotherapy for Parkinson's disease. | Hutter-Saunders JA et al. | β | 2011 | β |
| Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. | Bi M et al. | β | 2011 | β |
| Cytokine signaling in the human brain capillary endothelial cell line hCMEC/D3. | Fasler-Kan E et al. | β | 2010 | β |
| Effects of CBV, CBF, and blood-brain barrier permeability on accuracy of PASL and VASO measurement. | Wu CW et al. | β | 2010 | β |
| Induction of vascular endothelial growth factor and matrix metalloproteinase-9 via CD47 signaling in neurovascular cells. | Xing C et al. | β | 2010 | β |
| Neuroimaging for Lewy body disease: is the in vivo molecular imaging of Ξ±-synuclein neuropathology required and feasible? | Vernon AC et al. | β | 2010 | β |
| Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. | Poller B et al. | β | 2010 | β |
| Structure and function of the blood-brain barrier. | Abbott NJ et al. | β | 2010 | β |
| A gain-of-function screen in zebrafish identifies a guanylate cyclase with a role in neuronal degeneration. | Maddison LA et al. | β | 2009 | β |
| Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases. | Egleton RD et al. | β | 2009 | β |
| Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches. | Ciborowski P | β | 2009 | β |
| Blood-brain barrier alterations in ageing and dementia. | Popescu BO et al. | β | 2009 | β |
| Differential receptor-mediated drug targeting to the diseased brain. | Rip J et al. | β | 2009 | β |
| Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease. | Guo S et al. | β | 2009 | β |
| Emerging strategies for exploiting cannabinoid receptor agonists as medicines. | Pertwee RG | β | 2009 | β |
| Estimating blood and brain concentrations and blood-to-brain influx by magnetic resonance imaging with step-down infusion of Gd-DTPA in focal transient cerebral ischemia and confirmation by quantitative autoradiography with Gd-[(14)C]DTPA. | Knight RA et al. | β | 2009 | β |
| [Implication of the blood-brain barrier in neurological diseases: part II]. | Weiss N et al. | β | 2009 | β |
| Non-invasive visualization of CNS inflammation with nuclear and optical imaging. | Wunder A et al. | β | 2009 | β |
| Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment? | Staines DR et al. | β | 2009 | β |
| The blood-brain barrier in brain homeostasis and neurological diseases. | Weiss N et al. | β | 2009 | β |
| Adult neurogenesis, neuroinflammation and therapeutic potential of adult neural stem cells. | Taupin P | β | 2008 | β |
| Adult neurogenesis pharmacology in neurological diseases and disorders. | Taupin P | β | 2008 | β |
| [Alzheimer's disease: from brain lesions to new drugs]. | Forette F et al. | β | 2008 | β |
| Brain endothelial cell-cell junctions: how to "open" the blood brain barrier. | Stamatovic SM et al. | β | 2008 | β |
| Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. | Chen X et al. | β | 2008 | β |
| Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier. | Hartz AM et al. | β | 2008 | β |
| Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. | Wikoff WR et al. | β | 2008 | β |
| Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia. | McCaffrey G et al. | β | 2008 | β |
| Pathological and biochemical alterations of astrocytes in ovariectomized rats injected with D-galactose: a potential contribution to Alzheimer's disease processes. | Hua X et al. | β | 2008 | β |
| Pharmaceutical induction of ApoE secretion by multipotent mesenchymal stromal cells (MSCs). | Zeitouni S et al. | β | 2008 | β |
| Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. | Jellinger KA et al. | β | 2008 | β |
| The neuroscientist's melting pot: immunology, cell transplantation and other delivery systems, and enlightenment of disease etiology and treatment. | Eve DJ et al. | β | 2008 | β |
| Challenges in Neurorestoration: A Special Issue for the 14th Annual American Society for Neural Therapy and Repair (ASNTR) Meeting. | Emborg ME | β | 2007 | β |